Testing effectiveness (Phase 2)Ended earlyNCT01668173
What this trial is testing
HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET
Who this might be right for
Myeloproliferative Neoplasms
Memorial Sloan Kettering Cancer Center 7